The BMJ’s panel said their guideline “differs from others in that, after specifying a minimal LDL cholesterol level below which further lipid lowering is not appropriate, recommendations are based exclusively on the absolute benefits of these drugs on cardiovascular outcomes rather than meeting targets for LDL cholesterol level”.
They added: “Clinicians need to identify patient’s individual cardiovascular risks to apply these risk-stratified recommendations.”
The BMJ’s panel also said clinicians would need to take into account upcoming treatments when considering whether to prescribe additional medications for high cholesterol.
Professor Azeem Majeed of Imperial College London said the UK’s medicinal establishment needed to potentially update its guidance regarding cholesterol management.
if(typeof utag_data.ads.fb_pixel!==”undefined”&&utag_data.ads.fb_pixel==!0){!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod?n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);fbq(‘init’,’568781449942811′);fbq(‘track’,’PageView’)}
